2019 Volume No 38 – pages 94-105
Title: Complete regeneration of large bone defects in rats with commercially available fibrin loaded with BMP-2 |
Authors: M Koolen, A Longoni, J van der Stok, O Van der Jagt, D Gawlitta, H Weinans |
Address: Department of Orthopaedics, UMC Utrecht, G.05.228, P.O. Box 85500, 3508 GA Utrecht, the Netherlands |
E-mail: m.k.e.koolen at umcutrecht.nl |
Abstract: This study aimed at investigating in vitro and in vivo the efficiency of commercially available fibrin as a carrier for controlled and sustained bone morphogenetic protein-2 (BMP-2) release to induce bone formation and reduce the side effects of its use. In vitro release and activity of low-dose recombinant human BMP-2 (rhBMP-2) (37.5 µg/mL) embedded in commercially available fibrin were evaluated and, subsequently, critical-size femur defects in rats were grafted to study bone regeneration and vascularisation by micro-computed tomography (µCT) and histology. In vitro experiments showed a sustained BMP-2 release with a high BMP activity remaining after 28 d. In vivo, fibrin loaded with BMP-2 showed an extremely fast bone healing, with a large amount of new bone formation throughout the entire defect in the first 4 weeks and complete cortical repair and fusion after 8 weeks, with no ectopic bone formation. In contrast, the control fibrin group did not fuse after 12 weeks. Vascularisation was similar in both groups at 4 and 12 weeks after implantation. In conclusion, commercially available fibrin is a very efficient carrier for rhBMP-2 to graft critical-size cortical bone defects and might be a more optimal delivery vehicle for BMP-2-induced bone regeneration than currently available collagen sponges. |
Key Words: Preclinical studies, non-union, bone morphogenetic proteins, bioengineering, implants, injury/fracture healing. |
Publication date: September 17th 2019 |
Article download: Pages
94-105 (PDF file) |
